Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer

Détails bibliographiques
Auteurs principaux:	Douillard, J, Twelves, C, McKendrick, J, Bertetto, O, Coxon, F, Diaz-Rubio, E, Dufour, P, Maughan, T, Scheithauer, W, Burris, H
Format:	Journal article
Publié:	2004

Documents similaires